Neuroendocrine tumor of pancreas

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:97253
Who is this for?
Show terms as
3FDA treatments16Active trials29Specialists8Treatment centers

Where are you in your journey?

ℹ
UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Also known as:

Well-differentiated pancreatic neuroendocrine neoplasmWell-differentiated NEN of pancreasWell-differentiated pancreatic NENWell-differentiated neuroendocrine neoplasm of pancreasPancreatic NETPancreatic neuroendocrine tumorPNET
Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Jan 2026Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not

Uppsala University — NA

TrialRECRUITING
Sep 2025Patients With High-grade Pancreatic Neuroendocrine Tumors

National Cancer Center, Korea — PHASE2

TrialENROLLING BY INVITATION
Jul 2025Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Exelixis — PHASE2, PHASE3

TrialRECRUITING
Dec 2024Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

University of Chicago — PHASE1

TrialRECRUITING
Aug 2024Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

National Cancer Institute (NCI) — PHASE1

TrialRECRUITING
Jun 2024ATRX/DAXX in EUS-FNB Specimens of Pan-NETs

Azienda Ospedaliera Universitaria Integrata Verona

TrialACTIVE NOT RECRUITING
Jan 2024Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours

IRCCS San Raffaele

TrialRECRUITING
Jan 2024Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal Pancreatectomy

Fudan University — NA

TrialNOT YET RECRUITING
Nov 2023A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors

Changhai Hospital — PHASE2

TrialNOT YET RECRUITING
Nov 2023A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors

David Bushnell — EARLY_PHASE1

TrialACTIVE NOT RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

3 available

CABOMETYX

cabozantinib· Exelixis, Inc.
CABOMETYX is indicated for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic…

CABOMETYX is indicated for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET).

View Details →FDA Label ↗

Secreflo

Synthetic porcine secretin· ChiRhoClin, Inc.

Use in secretin stimulation testing for stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction

View Details →

Everolimus

EVEROLIMUS· Breckenridge Pharmaceutical, Inc.

Adults with progressive neuroendocrine tumors of pancreatic origin (PNET) that are unresectable, locally advanced or metastatic

View Details →FDA Label ↗

Clinical Trials

16 recruitingView all trials with filters →
Phase 31 trial
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
Phase 3
Actively Recruiting
PI: Ye Yuan, MD (RayzeBio Sr. Medical Director) · Sites: Phoenix, Arizona; Duarte, California +52 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Phase 25 trials
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
Phase 2
Actively Recruiting
PI: Willis Navarro, MD (Aadi Bioscience) · Sites: Newport Beach, California; Denver, Colorado +2 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Patients With High-grade Pancreatic Neuroendocrine Tumors
Phase 2
Enrolling by Invitation
PI: Sang Myung Woo(Principal), MD (National Cancer Center) · Sites: Goyang-si, Gyeonggi-do · Age: 19–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
Phase 2
Active
PI: Wu-Chou Su (National Cheng Kung University Hospital,Taiwan) · Sites: Kaohsiung City; Kaohsiung City +6 more · Age: 20–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
Phase 2
Active
PI: Timothy J. b, MD (Mayo Clinic) · Sites: Fairbanks, Alaska; Phoenix, Arizona +169 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Phase 2
Actively Recruiting
PI: Heloisa P Soares (SWOG Cancer Research Network) · Sites: Anchorage, Alaska; Anchorage, Alaska +446 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Phase 12 trials
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
Phase 1
Actively Recruiting
PI: Nikolaos Trikalinos (Yale University Cancer Center LAO) · Sites: Duarte, California; Irvine, California +8 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
Phase 1
Actively Recruiting
PI: Chih-Yi (Andy) Liao, MD (University of Chicago) · Sites: Chicago, Illinois · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
N/A3 trials
Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not
N/A
Actively Recruiting
PI: Olov Norlén, MD, PhD (Uppsala University Hospital) · Sites: Gothenburg; Lund +2 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 Patients
N/A
Actively Recruiting
· Sites: Utrecht · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Pancreatic Neuroendocrine Tumors
N/A
Actively Recruiting
PI: Fabrice CAILLOL, MD (Paoli Calmettes Institute) · Sites: Marseille · Age: 18–80 yrs
View on ClinicalTrials.gov ↗I'm interested →
Other3 trials
Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours
Actively Recruiting
· Sites: Milan, MI · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
ATRX/DAXX in EUS-FNB Specimens of Pan-NETs
Active
· Sites: Verona · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors
Actively Recruiting
PI: Xianjun Yu, MD, PhD (Fudan University) · Sites: Shanghai, Shanghai Municipality; Chengdu, Sichuan · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →

Specialists

Showing 25 of 29View all specialists →
DM
Diane Reidy-Lagunes, MD,MS
NEW YORK, NY
Specialist
PI on 1 active trial
SM
Saleh K Saleh, MD
Minya, Minya Governorate
Specialist

Rare Disease Specialist

PI on 5 active trials
AP
Annamaria Colao, MD, PhD
Specialist
PI on 3 active trials
AN
Aung Naing
Specialist
PI on 2 active trials
SO
Study Official
Specialist
PI on 9 active trials
SM
Steven A Rosenberg, M.D.
Specialist
PI on 19 active trials
NM
Ning Zhong, MD
SEATTLE, WA
Specialist
PI on 2 active trials
MM
Matthew Kulke, MD
SOUTH PORTLAND, ME
Specialist
PI on 2 active trials
JM
Jonathan Strosberg, MD
TAMPA, FL
Specialist
PI on 2 active trials
SH
Sebastien Hotte
Specialist
PI on 1 active trial
XP
Xianjun Yu, MD, PhD
Specialist
PI on 6 active trials
JP
Julian R. Molina, M.D., Ph.D.
Specialist
PI on 1 active trial
XM
Xiaowu Xu, MD
Specialist
PI on 2 active trials
LM
Lin Shen, MD
Specialist
PI on 8 active trials1 Neuroendocrine tumor of pancreas publication
NM
Nitya Raj, M.D
Specialist
PI on 1 active trial
SM
Stergios Moschos, MD
Chapel Hill, North Carolina
Specialist

Rare Disease Specialist

PI on 3 active trials
JW
Jeffrey Wong
Specialist
PI on 1 active trial
MP
Marjo Hahka-Kemppinen, MD, PhD
Specialist
PI on 1 active trial
AM
Atif Khan, MD
Specialist
PI on 1 active trial
PM
Peter Kingham, MD
Specialist
PI on 1 active trial
CP
Carmina Valle, PhD
Specialist
PI on 1 active trial
SM
Somashekar G Krishna, MD
Columbus, Ohio
Specialist

Rare Disease Specialist

SB
Stanislav Bezobchuk
Specialist
PI on 1 active trial
JC
Jennifer Ang Chan
Specialist
PI on 1 active trial
DF
Denis Ferreira
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center ↗

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center ↗

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program ↗

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site ↗

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site ↗

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site ↗

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine ↗

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program ↗

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Neuroendocrine tumor of pancreas.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Neuroendocrine tumor of pancreasForum →

No community posts yet. Be the first to share your experience with Neuroendocrine tumor of pancreas.

Start the conversation →

Latest news about Neuroendocrine tumor of pancreas

Disease timeline:

New recruiting trial: Metoprolol in Acute Respiratory Distress Syndrome (MAIDEN)

A new clinical trial is recruiting patients for Neuroendocrine tumor of pancreas

New trial: Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Phase PHASE1 trial recruiting. Ulixertinib

New trial: Evaluation of Endoscopic Ultrasound-Guided Radiofrequency Ablation for the Management of Pancreatic

Phase NA trial recruiting. Chemical Ablation

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Neuroendocrine tumor of pancreas

Are there clinical trials for Neuroendocrine tumor of pancreas?

Yes — 16 recruiting clinical trials are currently listed for Neuroendocrine tumor of pancreas on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Neuroendocrine tumor of pancreas?

25 specialists and care centers treating Neuroendocrine tumor of pancreas are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Neuroendocrine tumor of pancreas?

1 patient support program are currently tracked on UniteRare for Neuroendocrine tumor of pancreas. See the treatments and support programs sections for copay assistance, eligibility, and contact details.